BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 17493325)

  • 1. [Gene of DNA-dependent protein kinase catalylic subunit in chronic myeloid leukemia].
    Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):248-52. PubMed ID: 17493325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on mismatch repair genes of chronic myeloid leukemia].
    Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
    Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):103-6. PubMed ID: 16732964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
    Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
    Ernst T; Hoffmann J; Erben P; Hehlmann R; Hochhaus A; Müller MC
    Clin Chem Lab Med; 2008; 46(3):318-22. PubMed ID: 18303987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
    Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
    Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring twenty-six chronic myeloid leukemia patients by BCR-ABL mRNA level in bone marrow:a single hospital experience.
    Sakamoto Y; Mariya Y; Oshikiri T; Sasaki S; Segawa M; Teshiromori R; Ogura K; Akagi T; Kaimori M; Kubo K
    Acta Med Okayama; 2011 Oct; 65(5):335-42. PubMed ID: 22037271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
    Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
    Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
    Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.
    Karimiani EG; Marriage F; Merritt AJ; Burthem J; Byers RJ; Day PJ
    Exp Hematol; 2014 Mar; 42(3):183-191.e5. PubMed ID: 24269846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research advance on molecular genetics of CML blast crisis].
    Zhu HQ; Zhang S; Liu XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [SphK-1/S1P signal pathway in CML cells].
    Huang WR; Wang LS; Wang H; Duan HF; Li QF; Gao CJ; DA WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):730-3. PubMed ID: 18718048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
    Ma W; Tseng R; Gorre M; Jilani I; Keating M; Kantarjian H; Cortes J; O'Brien S; Giles F; Albitar M
    Haematologica; 2007 Feb; 92(2):170-5. PubMed ID: 17296565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia.
    Salesse S; Verfaillie CM
    Mol Cancer Ther; 2003 Feb; 2(2):173-82. PubMed ID: 12589034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
    Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ
    Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.